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Abstract
The p53 gene is rarely mutated in neuroblastoma, but codon 72 polymorphism that modulates its proapoptotic
activity might influence cancer risk and clinical outcome. We investigated whether this polymorphism affects
neuroblastoma risk and disease outcome and assessed the biologic effects of the p53-72R and p53-72P isoforms
in p53-null cells. Comparison of 288 healthy subjects and 286 neuroblastoma patients revealed that the p53-72
polymorphism had no significant impact on the risk of developing neuroblastoma; however, patients with the Pro/
Pro genotype had a shorter survival than those with the Arg/Arg or the Arg/Pro genotypes even in the stage 3 and
4 subgroup without MYCN amplification. By Cox regression analysis, the p53 Pro/Pro genotype seems to be an
independent marker of poor prognosis (hazard ratio = 2.74; 95% confidence interval = 1.14-6.55, P = .014)
together with clinical stage, MYCN status, and age at diagnosis. In vitro, p53-72P was less effective than p53-72R
in inducing apoptosis and inhibiting survival of p53-null LAN-1 cells treated with etoposide, topotecan, or ionizing
radiation but not taxol. By contrast, p53-72Pwasmore effective in promoting p21-dependent accelerated senescence,
alone or in the presence of etoposide. Thus, the p53-72 Pro/Pro genotype might be a marker of poor outcome in-
dependent of MYCN amplification, possibly improving risk stratification. Moreover, the lower apoptosis and the
enhanced accelerated senescence by the p53-72P isoform in response to DNA damage suggest that patients with
neuroblastoma with the p53-72 Pro/Pro genotype may benefit from therapeutic protocols that do not rely only on
cytotoxic drugs that function, in part, through p53 activation.
Neoplasia (2012) 14, 634–643
Introduction
Neuroblastoma (NB) is a childhood solid tumor that accounts for
8% to 10% of all childhood cancers and for ∼15% of all deaths be-
cause of pediatric malignancies [1]. NB arises from neuroectodermal
precursor cells of the neural crest, and therefore, tumors can develop
anywhere in the sympathetic nervous system [1]. Clinically, NB is
remarkably heterogeneous: age at diagnosis [2], clinical stage (based
on the International Neuroblastoma Staging System [3]), and tumor
histology [4] are the most important variables for predicting disease
risk and selecting appropriate therapeutic protocols. Children older
than 18 months, with tumor at advanced stage (3 or 4) or with un-
favorable histologic findings have an adverse outcome despite intensive
multimodal treatments such as high-dose myeloablative chemotherapy
followed by rescue with autologous bone marrow [5]. Clinical hetero-
geneity correlates with several genetic abnormalities whose detection
in tumor cells has further improved risk stratification [5]. V-myc
myelocytomatosis viral-related oncogene NB-derived (MYCN) onco-
gene amplification [6], hemizygous deletions of chromosomal region
1p36 [7], and unbalanced gain of 17q regions [8] are the most common
genomic aberrations in NB. MYCN amplification occurs in ∼20% of
cases and represents the most powerful marker of poor outcome [9]. In
contrast to other malignancies, only 2% to 3% of NBs have mutations
of the p53 gene [10]. p53 is a tumor suppressor gene that encodes for a
nuclear phosphoprotein, which, on activation, regulates many biologic
processes such as cell cycle checkpoints, apoptosis, and cellular senes-
cence [11]. Impairment of such processes has important implications
for clinical behavior and response to therapy of tumors with nonfunc-
tional p53 [12]. p53 also activates the transcription of the murine dou-
ble minute (MDM2) gene that encodes for the major negative regulator
of p53 [13]. In recent years, there has been an increasing interest in
identifying and assessing the frequency of gene variants (polymorphisms)
as a tool to predict interindividual cancer risk and response to cancer
therapies [14].
A polymorphism is defined as a DNA sequence change that occurs
in a significant proportion (>1%) of a large population [15]. The most
common type of genetic variation is a single nucleotide polymorphism
(SNP). For the p53 gene, an SNP has been identified at codon 72
within exon 4 causing an Arg>Pro substitution [16]. The p53-72R
isoform seems to be more potent than the p53-72P isoform in induc-
ing apoptosis, and increased mitochondrial localization and reduced
affinity of the p53-72R isoform for the p53 inhibitor iASPP are
among the proposed mechanisms that may be responsible for such
an effect [17,18].
In this study, we compared the frequency of the p53 codon 72 Arg/
Arg, Arg/Pro, and Pro/Pro genotypes in 288 control subjects and 286
newly diagnosed NBs and correlated these frequencies with clinical-
biologic variables such as age at diagnosis, primary tumor site, clinical
stage, and MYCN amplification. We report here that patients with
the Pro/Pro genotype, including those with normal MYCN status and
advanced disease stages, seem to have a shorter 5-year survival than
those with the Arg/Pro or Arg/Arg genotype.
The more aggressive disease of patients with NB with the Pro/Pro
genotype correlated with lower apoptosis and enhanced survival of
cytotoxic drug or ionizing radiation (IR)–treated p53-null LAN-1 cells
expressing the p53-72P compared with the p53-72R isoform. By con-
trast, expression of the p53-72P isoform, alone or in the presence of a
low concentration of etoposide, induced an increase in senescent cells.
Together, these findings suggest that, although relatively rare, the
p53 codon 72 Pro/Pro genotype might identify a subgroup of patients
with NB with aggressive disease independently of the status of other
markers predictive of poor outcome. Moreover, patients with this
genotype may respond less efficiently to treatments that induce DNA
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damage and increased p53 expression/activity and may benefit from
therapeutic protocols that include cytotoxic drugs with p53-independent
mechanisms of action.
Materials and Methods
Subjects
Two hundred eighty-six patients with NB (258 Italian patients,
most of whom were previously included to assess the frequency of
the MDM2 SNP-309 polymorphism [19] and 28 British patients)
were selected for the analysis of the p53 codon 72 genotype. Their
clinical and biologic characteristics are listed in Table W1. Tumor
DNA was analyzed in each patient, whereas peripheral blood DNA
was also genotyped in 40 cases to confirm that polymorphism fre-
quency did not reflect somatic mutation. Selection criteria were lack
of previous treatments and availability of adequate amount of DNA.
Tumor DNA was used because peripheral blood lymphocytes are not
always readily attainable from patients with NB. Institutional written
informed consent was obtained from parents or legal guardians of
patients with NB. The study underwent ethical review and approval
according to local institutional guidelines.
Controls
The p53 codon 72 genotype was also evaluated in peripheral blood
DNA of 288 healthy individuals from anonymous blood donors
randomly selected during a 5-year period (2000-2005) at several
Northern Italy Blood Banks and from control subjects stored at the
“Oncology Institute of Veneto,” Padova, Italy. Their age ranged from
25 to 60 years (median, 45 years) and the male-to-female ratio was
approximately 46% to 54%.
NB Cell Lines DNA
DNA from NB-69, NBL-W, NBL-S, BE1N, TR14, NGP,
NB1691, and LS NB cell lines was from Dr Tweddle’s laboratory,
whereas DNA from RN-GA, SH-EP, SK-, GI-CAN, and SK-NBE2
cell lines was from Dr Raschellà’s laboratory. DNA from LAN-5,
HTLA-230, GI-CAN, SH-SY5Y, IMR32, LAN-1, and SK-N-AS
cell lines was obtained using QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany) (Table W2).
p53 Codon 72 Genotyping
The p53 DNA segment for codon 72 genotype was amplified by
polymerase chin reaction (PCR) using 150 ng of DNA and a pair of
forward (5′-TTGCCGTCCCAAGCAATGGATGA-3′) and reverse
(5′-TCTGGGAAGGGACAGAAGATGAC-3′) primers that gener-
ated a 199-bp DNA product. DNA amplification was done as follows:
95°C for 1 minute, 60°C for 1 minute, and 72°C for 2 minutes for
40 cycles. PCR products were separated by electrophoresis in 1%
agarose gel with ethidium bromide, extracted using a PCR purification
kit (Roche Diagnostics GmbH, Mannheim, Germany), and each frag-
ment was sequenced from both ends on an ABI PRISM 377 DNA
Sequencer using the ABI PRISM Big Dye Terminator (PE Biosystem,
Foster City, CA). Thirty tumor and control DNA were independently
resequenced to confirm the genotype’s accuracy.
Statistical Analysis
The frequencies of p53 polymorphism at codon 72 were cross-
tabulated in patients with NB versus healthy controls using a two-sided
Fisher exact test. The frequencies of p53 polymorphism at codon 72
in patients with NB versus known prognostic factors were also cross-
tabulated using the Fisher exact test to evaluate the significance of
the association.
Clinical-pathologic variables were categorized as follows: age at diag-
nosis (<18 vs ≥18 months) [2], primary site (adrenal vs nonadrenal),
clinical stage according to the International Neuroblastoma Staging
System [3] (stage 1, 2, and 4 S vs 3 and 4), and MYCN status (single
copy vs amplified).
Five-year overall survival curves on the basis of the p53 genotype
at codon 72 in all patients with NB or in subgroups defined on the
basis of established prognostic factors were calculated according to
Kaplan and Meier [20], and the statistical significance of the differ-
ences was assessed using log-rank test. Cox multiple regression anal-
ysis [21] was carried out, including clinical stage,MYCN status, age at
diagnosis, and p53 polymorphism as covariates. All statistical tests
were two-sided, and P < .05 was considered statistically significant.
The analyses were carried out using the software package SPSS 11.0
for Windows (SPSS, Inc, Chicago, IL). The Hardy-Weinberg equilib-
rium was assessed by χ2 test.
Plasmids
p53-72R-ERTAM and p53-72P-ERTAM were generated as follows:
the p53-72R and p53-72P coding sequences were amplified by reverse
transcription–polymerase chain reaction from total RNA of ACN and
NBL-S cells, respectively. Sense primer (5′GTTAACATGGAG-
GAGCCGCA-3′) contains a 5′-flapping HpaI site flanked by the ATG,
and antisense primer (5′GGATCCGTCTGAGTCAGGC-3′) contains a
5′-flapping BamHI and a mutated p53 stop codon. The ligand-binding
domain of the mutated (Gly525Arg) tamoxifen-responsive murine
estrogen receptor (ER) was obtained by BamHI/EcoRI digestion of
the ΔuORF-C/EBPα-ERTAM vector [22]. Each PCR product and the
digested ERTAM fragment were subcloned into the HpaI/EcoRI–
digested MigRI vector.
Cells Cultures and Retroviral and Lentiviral Infections
p53-null human NB cell line LAN-1 [23] was cultured in Dulbecco
modified Eagle medium with Glutamax (Invitrogen-GIBCO, Carlsbad,
CA) supplemented by 10% fetal bovine serum and penicillin and strep-
tomycin (100 μg/ml each) at 37°C, 5% CO2. For retroviral infections,
Phoenix cells were transiently transfected with the indicated plasmids.
The infectious supernatant was collected 48 hours later and was used to
infect (a 48-hour procedure) LAN-1 cells. Twenty-four hours later,
infected cells were sorted (EPICS Profile Analyzer; Coulter, Hialeah,
FL) for green florescent protein (GFP) expression and maintained in
culture as described [24].
For lentiviral infections, 293T cells were cotransfected with
p21shRNA pLKO.1 (20 μg) and the packaging plasmids pCMVd8.2
(10 μg) and pCMV-VSVG (15 μg) using the calcium phosphate
transfection kit (Invitrogen). Lentiviral stocks were harvested 48 hours
later, centrifuged for 5 minutes at 3000 rpm, aliquoted, and stored at
−80°C. Lentiviral titers were determined by transduction of 3 × 104
293T cells with serial dilutions of the viral stocks in 24-well plates sup-
plemented with puromycin (2 μg/ml). Then, LAN-1-p53-72R-ER or
LAN-1-p53-72P-ER plated at a cell density of 2 × 104 cells per well and
transduced with a multiplicity of infection of 10 using one round of
cosedimentation and incubation. Lentivirally transduced cells were
selected in the presence of puromycin (2 μg/ml).
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Protein Analysis
Cell lysates from 5 × 105 cells were suspended in 50 μl of 2×
Laemmli lysis buffer (BioRad, Richmond, CA) and boiled for 10 min-
utes. For Western blot analysis, 20 μl (equivalent to 200,000 cells) was
resolved by 10% SDS-PAGE, transferred to nitrocellulose membranes,
and blotted with the indicated antibodies: anti-p53 (DO-1, sc-126;
Santa Cruz Biotechnology, Santa Cruz, CA), anti–phospho Ser-15 p53
(no. 07-388; Cell Signaling), anti–β-actin (sc-47778; Santa Cruz Bio-
technology), anti-p21 (DF10; Calbiochem, San Diego, CA), and anti-
MDM2 (no. 0P46; Calbiochem). Secondary antibodies were peroxidase
labeled, and peroxidase was detected with Enhanced Chemiluminescence
Kit (Amersham Pharmacia Biotech, Little Chalfont, United Kingdom).
Irradiation Treatment
Cells were irradiated with different x-ray doses (20, 40, and 80 cGy)
using a Gilardoni x-ray generator (Gilardoni SpA, Mandello del Lario,
Lecco, Italy). Irradiation times varied from 15 to 30 seconds depending
on the dose. After irradiation, medium was changed, and cells were kept
at 37°C in the incubator for 24 hours. Subsequently, cells were plated
for colony formation assays or used for flow cytometric measurements
carried out after an additional 48 hours (72 hours after irradiation).
Flow Cytometry Analysis
Cells were harvested, and pellets were washed twice with PBS and
diluted in 2× Nicoletti solution (0.1% Na citrate, 0.1% Triton X-100,
50 μg/ml propidium iodide) for 5 minutes before the analyses. Samples
were analyzed by flow cytometry using a FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA). For each sample, at least 2 × 104 cells
were analyzed. Cell cycle distribution and hypodiploid DNA content
were calculated by Cell Quest software (BD Biosciences). Statistical
significance (P) was calculated by two-tailed Student’s t test.
Confocal Immunofluorescence
LAN-1 (parental and p53-ER–derivative) cells were plated on
Culture Slides (BD Falcon) and, 36 hours later, treated with 250 nM
4-hydroxy-tamoxifen (4-HT). After 2 hours, cells were washed twice
this PBS, fixed with ice-cold methanol for 20 minutes, permeabilized
in 0.1% Triton X-100 in PBS (5 minutes), washed twice with PBS,
and blocked in 1% bovine serum albumin/PBS for 30 minutes at
room temperature.
Slides were stained with an anti-p53 monoclonal antibody (PAb
1801; Calbiochem) diluted 1:80 in 5% milk–Tris-buffered saline
and Tween 20, incubated for 1 hour at room temperature. After a
30-minute incubation at room temperature with antirabbit Alexa
Fluor 555 conjugate (A-21428; Invitrogen) diluted 1:300 in 5% milk–
Tris-buffered saline and Tween 20, slides were washed three times in
PBS and rinsed in water. For nuclei staining, Hoechst 33258 was
added in the last PBS wash. As control, LAN-1 cells were stained in
the absence of the anti-p53 antibody. Cells were visualized by Leica
TCS SP2 confocal laser scanner microscope (Leica Microsystems,
Wetzlar, Germany) using a 40× oil immersion objective, and images were
analyzed with Leica software.
Colony Assay
Parental, p53-72R-ER, and p53-72P-ER–derivative LAN-1 cells
were seeded at 3 × 105 cells per well in six-well plates. The following
day, cells were treated with etoposide (5, 10 or 20 μM) or taxol
(2 μM). After 3 hours, cells were washed and seeded (5 × 103, 1 × 104,
2 × 104 cells per plate) in six-well plates with or without 4-HT
(250 nM). After 7 days, plates were stained with Crystal violet, and
colonies were counted.
SA-β-gal Staining Assay
The staining for SA-β-galactosidase activity was performed as
described [25]. Briefly, cells were seeded in 24-well plates and treated
with 4-HT alone (250 nM, 48 hours) when 80% confluent or with
4-HT and etoposide (25 nM etoposide for 3 hours and then 250 nM
4-HT for 48 hours) when 50% confluent. At the end of the treatment,
cells were washed in PBS and fixed in 2% formaldehyde/0.2% glutar-
aldehyde. Cells were then washed and incubated at 37°C for 4 hours
with fresh SA-β-gal staining solution (1 mg of 5-bromo-4-chloro-3-
indolyl-β-D-galactoside per milliliter, 40mM citric acid/sodium phosphate
[pH 6.0], 150mMNaCl, 2 mMMgCl2, 5 mMpotassium ferricyanide).
Real-time PCR Expression Analyses
For real-time quantitative PCR, total RNA was isolated from p53-
72R-ER- and p53-72P-ER-LAN-1 cells using the RNeasy Mini kit
(Qiagen). RNA was treated for 1 hour at 37°C with DNase-RNase
free (Roche Applied Science, Mannheim, Germany), which was then
deactivated for 15 minutes at 65°C. Four micrograms of total mRNA
was reverse-transcribed using SuperScript III Reverse Transcriptase kit
(Invitrogen), and the resulting complementary DNA was used as a
PCR template. All reactions were done in triplicate, and total RNA was
extracted from two separate experiments.
Primer pairs of analyzed genes (MDM2: FW 5′-caagttactgtgtatcagg-
caggg-3′, RV 5′-tctgttgcaatgtgatggaagg-3′; BAX: FW 5′-ggagcgg-
cggtgatggac-3′, RV 5′-ggcccctgtcttcatgatctgc-3′; NOXA: FW 5′-
cagagctggaagtcgagtgtg-3′, RV 5′-gttcctgagcagaagagtttgg-3′; PERP: FW
5′-cccgtgaagtacacccagacc-3′, RV 5′-gcccacccaaagccgtagg-3′; PAI-1: FW
5′-aagactcccttccccgactc-3′, RV 5′-cacagagacagtgctgccgt-3′; p21: FW 5′-
cctgcccaagctctaccttcc-3′, RV 5′-ggtccacatggtcttcctctgc-3′; HPRT: FW
5′-agactttgctttccttggtcagg-3′, RV 5′-gtctggcttatatccaacacttcg-3′) were de-
signed using BeaconDesign software (Premier Biosoft International, Palo
Alto, CA). Real-time quantitative PCR was performed using GoTaq
qPCR Master Mix (Promega, Madison, WI) on a MyIQ thermocycler
(BioRad) and quantified using MyIQ software (BioRad) that analyzes the
Ct value of real-time PCR data with the ΔΔC t method.HPRT, a house-
keeping gene with constant expression, was used as an internal control
to normalize input complementary DNA.
Results
Frequency and Association with Poor-Prognosis
Predictors of p53-72 Genotypes
Genotype frequencies at codon 72 of p53 (Arg/Arg, Arg/Pro, and
Pro/Pro) and other genetic and clinical characteristics of patients with
NB included in this study are summarized in Table W1. The geno-
type frequencies in all groups were within the Hardy-Weinberg equi-
librium. The frequency of the Pro/Pro genotype in tumor DNA was
not significantly different from that of peripheral blood samples of
control subjects (3.8% vs 6.6%, P = .190); no statistical significance
was also noted if the comparison was limited to the Italian control and
NB cohorts (not shown). In 40 cases tested, peripheral blood and tumor
DNA genotypes were identical indicating that polymorphism frequency
did not reflect somatic mutation or loss of heterozygosity/copy number
gains which are uncommon in NB for region 17p13 [26], the chromo-
somal location of the p53 gene. In an attempt to validate independently
the frequency of the p53-72 Pro/Pro genotype in a larger cohort of
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patients with NB, we searched the dbGaP database (http://www.ncbi.
nlm.nih.gov/gap), which contains the data set of Wang et al. [27] with
1627 patients with NB and 3254 genetically matched disease-free con-
trols. However, data for the p53-72 SNP (rs1042522) were not available
because the array platforms used in the Wang et al. data set (Illumina
HumanHap550v3.0, HumanHap550v1.1, and Human610_Quadv1_B)
do not assay the rs1042522 SNP.
Of interest, the frequency of the Pro/Pro genotype was low (1/20,
5%) also in human NB cell lines (Table W2). We then assessed
whether the p53-72 Pro/Pro genotype was associated with predictors
of poor outcome such as advanced clinical stage (3 and 4), age at diag-
nosis 18 months or older, adrenal primary site, and MYCN ampli-
fication (Table 1). A statistically significant association of the Pro/Pro
genotype with age 18 months or older (P = .031) was noted; although
not statistically significant, the Pro/Pro genotype was more represented
in patients with unfavorable stage (3 and 4), and seemed to be inversely
associated with MYCN amplification (Table 1). In particular, of the
seven patients with stage 4 disease with the Pro/Pro genotype, only
one had MYCN amplification.
Effect of p53-72 Genotypes on Survival
Cumulative Kaplan-Meier 5-year overall survival of patients with
NB with the Pro/Pro genotype was shorter than that of patients with
the Arg/Arg (P = .042, log-rank test) or the Arg/Pro genotype (P = .003,
log-rank test). Because survival of patients with the Arg/Arg and the
Arg/Pro genotype was undistinguishable, we decided to combine these
two groups and compare to the Pro/Pro group in all the analyses. As
shown in Figure 1A, patients with the Pro/Pro genotype had a shorter
survival that those with the Arg/Arg and Arg/Pro genotypes (P = .014,
log-rank test). Moreover, in the NB subgroup with normal MYCN
status, patients with the Pro/Pro genotype had a shorter overall survival
than those with the Arg/Arg and Arg/Pro genotypes (P = .005, log-rank
test; Figure 1B). In this subgroup, overall survival of patients with the
Pro/Pro genotype was also shorter when limiting the analysis to those
either at stage 3 and 4 or at stage 4 only (P = .008 and P = .003, re-
spectively, log-rank test; Figure 1,C andD). We also observed a shorter
overall survival in patients with the Pro/Pro genotype in the subgroups
at stage 4, with age 18 months or older, and with normalMYCN status
(P = .013; Figure W1).
The p53 Codon 72 Polymorphism Is an Independent
Prognostic Factor
Because the p53 codon 72 Pro/Pro genotype was associated with a
shorter overall survival, we asked whether it might represent an inde-
pendent factor distinct from other common NB prognostic indicators
such as clinical stage, MYCN status, and age at diagnosis. Thus, we
carried out a Cox multiple regression analysis for overall survival that
included stage,MYCN status, age at diagnosis, and p53 codon 72 geno-
types as covariates. Interestingly, the hazard ratio between Pro/Pro and
Arg/Arg or Arg/Pro genotypes was significant (2.74; 95% confidence
interval [CI] = 1.14-6.55, P = .024; Table 2), suggesting that the
p53-72 Pro/Pro genotype may represent an additional independent
prognostic marker in NB.
Biologic Effects of p53-72R and p53-72P in NB Cells
To address potential mechanisms associated with the more aggressive
disease in patients with NB with the p53-72 Pro/Pro genotype, we es-
tablished p53-null LAN-1 derivative cell lines expressing the tamoxifen
(4-HT)-regulated p53 72R-ER or p53 72P-ER isoform (Figure W2)
and assessed whether their activation modulates differentially the effects
of cytotoxic drugs or IR on apoptosis, survival, and senescence.
For the experiments assessing the effects of cytotoxic drugs on apop-
tosis and survival, we selected etoposide and topotecan because they
are used to treat patients with NB and function, in part, through DNA
damage-dependent p53 activation and also taxol because its mechanism
of action is p53 independent [28,29].
As expected, the frequency of apoptotic cells (measured by hypo-
diploid DNA content) on treatment with etoposide or topotecan and
4-HT was higher in LAN-1-p53-72R-ER or in LAN-1-p53-72P-ER
than in parental cells (Figure 2, A and C ). However, LAN-1-p53-
72P-ER cells showed less apoptosis than LAN-1-p53-72R-ER cells
did (Figure 2, A and C ); such lower apoptosis correlated with an in-
crease in the number of surviving cells measured by clonogenic assays
Table 1. Association of p53-72 Polymorphism with Clinical and Genetic Characteristics of Patients
with NB.
Feature p53 Arg72Pro
Arg/Arg or Arg/Pro (%) Pro/Pro (%) P*
Stage .338
1-2-4 S 98 (98.0) 2 (2.0)
3-4 172 (95.0) 9 (5.0)
MYCN .304
Non amp 205 (95.3) 10 (4.7)
Amp 69 (98.6) 1 (1.4)
Age .031
<18 mo 115 (99.1) 1 (0.9)
≥18 mo 158 (94.0) 10 (6.0)
Site .523†
Extra adrenal 139 (97.2) 4 (2.8)
Adrenal 121 (95.3) 6 (4.7)
Multiple sites 1 (100.0)
Amp indicates amplified; non amp, non amplified.
*P: two-tailed Fisher exact test.
†P value was calculated by comparing tumors with adrenal and extra-adrenal localization only.
Figure 1. Kaplan-Meier 5-year cumulative overall survival on the
basis of p53-72 genotypes in all NBs (A), NBs with normal MYCN
status (B), stage 3 and stage 4 NBs with normal MYCN status (C),
stage 4 NBs with normalMYCN status (D). Solid line indicates Arg/
Arg or Arg/Pro genotype; dashed line, Pro/Pro genotype.
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(Figure 2, B and D). As expected, cytotoxic drug plus 4-HT–treated
parental cells were more clonogenic than the LAN-1-p53-72R/P-ER
counterpart (Figure 2, B and D). The frequency of apoptosis and the
number of clonogenic/surviving cells were comparable in LAN-1 cells
(parental, p53 72R-ER, p53 72P-ER) treated with etoposide or topo-
tecan only (not shown).
Compared with parental cells, treatment of LAN-1-p53-72R-ER
or p53-72P-ER cells with 4-HT did not enhance taxol-induced
apoptosis (measured by DNA content in cells treated with 4-HT
for 24 hours), probably because of the lack of p53-Ser 15 phosphor-
ylation (Figure 3, A and B). Likewise, the surviving/clonogenic frac-
tion of taxol-treated parental or LAN-1-p53-ER cells was essentially
identical (Figure 3C , upper panel ). Compared with parental cells, co-
treatment with 4-HT and taxol markedly suppressed colony formation/
survival of LAN-1-p53-ER cells, but there was no statistically signifi-
cant difference in the effects of p53-72R and p53-72P (Figure 3C ,
lower panel).
As with etoposide and topotecan, treatment with IR (40 cGy) led
to higher apoptosis in 4-HT–treated LAN-1-p53-72R-ER and LAN-
1-p53-72P-ER than parental cells (Figure 2E ). Likewise, apoptosis
was more frequent in 4-HT–treated LAN-1-p53-72R-ER than in
LAN-1-p53 72P-ER cells (Figure 2E ). Conversely, the number of
surviving cells measured by clonogenic assays was significantly higher
in 4-HT– and IR- (40 or 80 cGy) treated LAN-1-p53-72P-ER than
LAN-1-p53-72R-ER cells (Figure 2F ). No statistically significant
differences were noted in the frequency of apoptosis and clonogenic
cells after treatment of LAN-1 cells (parental, p53 72R-ER,-p53
72P-ER) with IR only (not shown).
The effect of p53-72R or p53-72P activation on accelerated senes-
cence was investigated upon treatment of parental and LAN-1-p53-
ER cells with 4-HT alone or with a low concentration of etoposide
(25 nM). Treatment with 4-HT alone induced a higher frequency of
SA-β-gal–positive cells in LAN-1-p53-72P than in LAN-1-p53-72R
cultures (Figure 4A); such a difference was also observed in LAN-1-
p53-72 cells co-treated with 4-HT and etoposide (Figure 4B). By
contrast, SA-β-gal positivity was barely detectable or clearly lower
in parental cells treated with 4-HT only or with 4-HT and etoposide
(Figure 4, A and B).
Differential Expression of p53-Regulated Genes in
LAN-1-p53-72R and LAN-1-p53P Cells
To assess whether the differences in survival and senescence of
cytotoxic drug- or IR-treated LAN-1-p53-72 isoform-specific cells
may be explained by differences in the levels of p53-regulated genes,
the expression of some of these genes was assessed by real-time PCR
in 4-HT–treated LAN-1-p53-72R and LAN-1-p53-72P-ER cells.
Among the genes tested, levels of BAX and MDM2 were unchanged;
by contrast, the expression of NOXA and PERP was higher in 4-HT–
treated LAN-1-p53-72R cells, whereas the levels of the CDK inhib-
itor p21 and PA-I (at least at 12 hours) were higher in 4-HT–treated
LAN-1-p53-72P cells (Figure W3).
Table 2. Five-Year Overall Survival Analysis.
Feature Univariate
(Kaplan-Meier)
Cox Multiple Regression
% Survival P P Hazard Ratio 95% CI
Stage
1-2-4 S 85.0
3-4 54.8 <.001 .03 3.09 1.47-6.48
MYCN status
Non amp 71.9 <.001 <.001 3.15 1.86-5.36
Amp 41.0
Age
<18 mo 86.5 <.001 .013 2.31 1.19-4.48
≥18 mo 51.1
p53 codon 72
Arg/Arg or Arg/Pro 67.0 .014 .024 2.74 1.14-6.55
Pro/Pro 30.0
CI indicates confidence interval.
Figure 2. Frequency of apoptotic (A, C, and E) and clonogenic cells (B, D, and F) in cytotoxic- or IR-treated LAN-1 (parental, p53-72R, or
p53-72P) cells on 4-HT–dependent activation of p53. In B, D, and F, histograms show residual colony formation of cytotoxic- or IR- and 4-HT–
treated LAN-1 (parental, p53-72R, or p53-72P) cells compared with that of cells treated with cytotoxic drug or IR only. Results are presented
as the mean ± SD of three experiments performed in triplicate. *P < .05.
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Figure 3. Frequency of apoptotic and clonogenic cells in taxol- or taxol and 4-HT–treated LAN-1 (parental, p53-72R, or p53-72P) cells.
(A) Western blot shows levels of p53 Ser-15 phosphorylation in LAN-1 (parental, p53-72R, or p53-72P) cells treated with taxol or etoposide
(positive control) and 4-HT. (B) Histograms show percent apoptosis (hypodiploid DNA content). (C) Residual colony formation after treat-
ment of LAN-1 (parental, p53-72R, p53-72) cells with taxol or taxol and 4-HT. Results are presented as the mean ± SD of three (B) or two
(C) experiments performed with three different seeding (C). NS indicates not significant, P > .05.
Figure 4. Frequency of senescent (SA-β-gal–positive) cells in parental or LAN-1-p53-ER cultures treated with 4-HT alone (A) or co-treated
with etoposide (B). In A, parental, LAN-1-p53-72R-, or p53-72P-ER cells were treated with 4-HT (250 nM; 48 hours) and percent of SA-β-gal–
positive cells was determined by counting 600 cells; histograms represent the results (mean ± SD) of three independent experiments per-
formed in triplicate. In B, parental, LAN-1-p53-72R-, or p53-72P-ER cells were treated with a suboptimal concentration of etoposide (25 nM;
3 hours), washed and treated with 4-HT (250 nM; 48 hours). In each experiment, 1000 cells were scored for SA-β-gal positivity. Histograms
represent the results (mean ± SD) of two experiments performed in duplicate.
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The difference in p21 expression between 4-HT–treated LAN-1-
p53-72P and LAN-1-p53-72R cells was confirmed by Western blot
analysis (Figure W4).
To assess whether the differential expression of p21 in 4-HT–treated
LAN-1-p53-72P- and LAN-1-p53-72R-ER cells had any effect on the
biologic response of etoposide-treated cells, we measured apoptosis, col-
ony formation, and senescence (SA-β-gal positivity) in p21-silenced
LAN-1-p53-72R- and LAN-1-p53-72P-ER cells (Figure 5A). Down-
regulation of p21 expression had no effect on the apoptosis and survival
of etoposide/4-HT–treated LAN-1-p53-72R and LAN-1-p53-72P
cells (Figure W5); by contrast, SA-β-gal–positive cells were markedly
reduced on down-regulation of p21 expression (compare Figure 4B
with Figure 5B; % SA-β-gal positivity in p53-72-ER vs p53-72-ER
p21-sh cells: 30.85% ± 6% vs 17.32% ± 2% in cells expressing p53-
72R and 54.24% ± 3% vs 30.87% ± 4% in cells expressing p53-72P,
respectively). However, senescent cells remained more numerous in
etoposide/4-HT–treated p53-72P- than p53-72R-ER-LAN-1 cultures
(Figure 5B), consistent with p53 isoform-specific regulatory mecha-
nisms independent of p21.
Discussion
Genetic characteristics associated with tumor initiation and/or progres-
sion and predictive of clinical outcome are a subject of intense investi-
gation. Several recent studies have analyzed the relation between the
polymorphism of p53 codon 72 and cancer development, disease pro-
gression, response to chemotherapy, and overall survival. In several
studies, the p53-72Arg/Arg genotype was associated with increased
risk for breast [30,31], gastric [32], ovary [33], oral [34], skin cancer
[35], and sporadic colorectal adenocarcinoma [36]. On the contrary,
other studies have demonstrated an association between the Pro/Pro geno-
type and increased risk for non–small cell lung [37], nasopharyngeal
[38,39], thyroid [40], and skin cancer [41]. The reasons for these dis-
crepancies might depend on methodological differences in the studies
(laboratory and statistical analyses, selection of patients, and control
subjects) and/or true geographic and ethnic variations. Instead, more
consistent results were obtained when assessing the correlation between
p53 codon 72 allelic variants and tumor progression, patients’ response to
chemotherapy, and overall survival [42–45]. In these studies, patients
with the Pro/Pro genotype had a worse outcome than those with the
Arg/Arg genotype, probably reflecting different biologic properties of
the two p53 variants. The p53-72R isoform has been shown to be more
effective of the 72P isoform in inducing apoptosis, a difference possibly
explained by its more efficient mitochondrial localization and/or re-
duced affinity for iASPP, a member of the ASPP family which inhibits
the transactivating and apoptotic functions of p53 [17,18].
Thus, we analyzed the frequency of p53-72 genotypes in DNA sam-
ples of patients with NB and their association with disease extent and
clinical outcome. Because the p53 gene is rarely mutated in NB, it is
conceivable that the expression of a p53 isoform with reduced proapop-
totic activity may have a negative impact on cancer risk and clinical
outcome. Although there was no association between any of the p53
codon 72 genotypes and risk to develop NB, patients with the p53-
72 Pro/Pro genotype had a shorter overall survival compared to those
with the Arg/Arg and Arg/Pro genotypes. Of interest, overall survival of
patients with the Arg/Arg and the Arg/Pro genotypes was undistin-
guishable; this observation is consistent with a number of possibilities
(which can be tested experimentally) such as functional dominance
of the p53-72R over the p53-72P isoform or unequal levels of isoform
expression when both p53-72 alleles are present.
Although caution is necessary because of the groups’ small size, a
decrease in overall survival in patients with the Pro/Pro genotype was
also observed in the subgroup with no MYCN amplification, includ-
ing patients at stages 3 and 4 or at stage 4 only. These findings are
intriguing and potentially important because amplification of MYCN
is the most common and reliable marker of poor outcome, especially
in infants (children <1 year at diagnosis) with stage 4 disease [46].
Nevertheless, a substantial part of older children with stage 4 NB has
a dismal outcome despite the absence of MYCN amplification [47]. In
these patients, the genetic trait(s) responsible for tumor aggressiveness
are still under investigation [47]. The association of the p53-72 Pro/Pro
genotype with shorter overall survival in the subgroup of patients with
stage 3 and 4 disease withoutMYCN amplification raises the possibility
that it may be one of the factors promoting tumor aggressiveness in
stage 4 disease with normal MYCN status. That the p53-72 Pro/Pro
genotype might be a marker of poor outcome in NB is further sup-
ported by the results of the Cox multiple regression analysis, which sug-
gest the independence of this polymorphism from other commonly used
prognostic indicators such as clinical stage, age at diagnosis, and MYCN
status. Consistent with these data, of 20 NB cell lines examined, the
Figure 5. Frequency of SA-β-gal–positive cells in p21-silenced
LAN-1-p53-72R- and LAN-1-p53-72P-ER cell cultures. (A) Western
blot shows expression of p21, MDM2, and β-actin in 4-HT–treated
parental or p21 shRNA–lentivirally transduced LAN-1-p53-72R- and
LAN-1-p53-72P-ER cells. Levels of MDM2 and β-actin were mea-
sured as control for specificity and loading, respectively. (B) Histo-
grams (mean ± SD of two experiments) show percent SA-β-gal
positivity in 4-HT/etoposide–treated p21 shRNA–lentivirally trans-
duced LAN-1-p53-72R- and LAN-1-p53-72P-ER cells.
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only one with the p53-72 Pro/Pro genotype is the NBL-S line, which
has an aggressive behavior in mice and normal MYCN status [48],
although the half-life of N-myc protein in NBL-S cells is longer than
normal [48].
Experiments carried out using etoposide, topotecan, or IR-treated
p53-null LAN-1 derivative cell lines expressing the 4-HT–regulated
p53-72R-ER or p53-72P-ER isoform support the hypothesis that
NB cells from patients with the p53-72 Pro/Pro genotype exhibit
an increased survival and a reduced propensity to undergo apoptosis.
However, in the p53-72-ER-LAN-1 cell lines treated with taxol, a
drug with p53-independent mechanism of action [27,28], the effects
of the two p53 isoforms were essentially undistinguishable. Based on
these data, it is reasonable to speculate that patients with NB with
the p53-72 Pro/Pro genotype may benefit more from co-treatment
with drugs that induce DNA damage and increase p53 expression
(e.g., topoisomerase I or II inhibitors or IR) and drugs with p53-
independent mechanisms of action.
Of interest, p53-72P was more effective than p53-72R in promot-
ing the appearance of senescent (β-gal–positive) cells in vitro. Al-
though it is unknown whether enhanced senescence would also be
associated with activation of p53 in NB with the p53-72 Pro/Pro
genotype, it is conceivable that undergoing p53-dependent accelerated
senescence rather than apoptosis may allow some NB cells to escape
cytotoxic drug–induced killing through cell-autonomous and/or para-
crine mechanisms [49,50].
In summary, although relatively rare, the p53 codon 72 Pro/Pro
genotype might be relevant for improving risk stratification and, per-
haps, selecting more personalized therapeutic protocols. In light of
the results of this pilot study, further investigations in a larger num-
ber of patients and in mouse models of NB are warranted to validate
the impact of this p53 polymorphism as a prognostic marker and
modulator of chemotherapy sensitivity.
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Table W1. Clinical-Biologic Characteristics of Patients with NB at Diagnosis.
Feature Levels n (%)
p53 codon 72 Arg/Arg 181 (63.3)
Arg/Pro 94 (32.9)
Pro/Pro 11 (3.8)
Total 286
Stage* 1 47 (16.7)
2 39 (13.9)
3 55 (19.6)
4 126 (44.8)
4 S 14 (5.0)
Total 281
MYCN* Non amp 215 (75.4)
Amp 70 (24.6)
Total 285
Age* <18 mo 116 (40.8)
≥18 mo 168 (59.2)
Total 284
Site* Adrenal 127 (47.0)
Extra-adrenal 143 (53.0)
Total 270
Amp indicates amplified; non amp, non amplified.
*Information is not available for all patients with NB.
Table W2. Genetic Characteristics of NB Cell Lines.
Lines p53-Codon 72 MYCN Status
LAN-5 Arg Amp
SH-EP Arg Non amp
HTLA-230 Arg Amp
RN-GA Arg NA
GI-CAN Arg/Pro Non amp
SK-NBE2C Arg Amp
SY-5Y Arg Non amp
SK-N-AS Arg Non amp
ACN Arg Non amp
SK-NBE2 Arg NA
IMR32 Arg Amp
LAN-1 Arg Amp
NB-69 Arg Non amp
NBL-W Arg Amp
NBL-S Pro/Pro Non amp
BE1N Arg/Pro NA
TR14 Arg/Pro Amp
NGP Arg/Pro Amp
NB1691 Arg Amp
LS Arg Amp
NA indicates not available.
Figure W1. Kaplan-Meier 5-year cumulative overall survival on the
basis of p53-72 genotypes in stage 4 NBs with normal MYCN sta-
tus and age 18 months or older. Solid line indicates Arg/Arg or Arg/
Pro genotype; dashed line, Pro/Pro genotype.
Figure W2. Schematic representation (A), expression (B), and subcellular localization (C) of the 4-HT–regulated p53-72R and p53-72P
isoforms in p53-null LAN-1 cells. LAN-1 cells were retrovirally transduced with MigRI/GFP-p53-72R-ER orMigRI/GFP-p53-72P-ER (A) and
p53 expression and subcellular localization was assessed by Western blot analysis (B) and confocal microscopy (C), respectively. Nu-
clear accumulation of p53-ER after treatment with 4-HT (250 nM) was detected using Alexa Fluor 555 secondary antimouse antibody.
Nuclei were counterstained with Hoecsht 33258.
Figure W3. Expression of p53-regulated genes in 4-HT–treated LAN-1-p53-72R and LAN-1-p53-72P cells. Histograms show expression
of p53-regulated genes detected by real-time PCR.
Figure W4. Expression of p21 in 4-HT–treated LAN-1-p53-72R and LAN-1-p53-72P cells. Western blot (left panel) and normalized
densitometric analysis (right panel) show expression of p21 in 4-HT–treated LAN-1-p53 cells.
Figure W5. Effect of p21 silencing on apoptosis and survival of 4-HT
and etoposide-treated LAN-1-p53-72R and LAN-1-p53-72P cells.
Histograms show (A) apoptosis and (B) colony formation of 4-HT
and etoposide-treated p21-silenced LAN-1-p53-72R and LAN-1-
p53-72P cells.
